Close Menu

NEW YORK (GenomeWeb) – Ginkgo Bioworks today announced it has acquired several assets from Warp Drive Bio, a subsidiary of Revolution Medicines, including its genome mining platform.

Warp Drive's bioinformatics technology sifts through microbial genome databases to uncover potential antibiotics. Its genomic database includes more than 135,000 bacterial strains.

Under the terms of the deal, Ginkgo will obtain Warp Drive's genomic sequence collection and bioinformatics software. Warp Drive's genome mining team will also move to Ginkgo's headquarters in Boston.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.

Bloomberg reports that BGI's SARS-CoV-2 testing sites in the Middle East have raised concerns among US officials.

A new Pew Research Center poll finds confidence in medical researchers has grown among US adults since the start of the coronavirus pandemic.

In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.